|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SARS |
Gene summary for SARS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SARS | Gene ID | 6301 |
| Gene name | seryl-tRNA synthetase 1 | |
| Gene Alias | NEDMAS | |
| Cytomap | 1p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q5T5C7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6301 | SARS | LZE4T | Human | Esophagus | ESCC | 1.87e-08 | 4.65e-01 | 0.0811 |
| 6301 | SARS | LZE7T | Human | Esophagus | ESCC | 1.73e-04 | 6.69e-01 | 0.0667 |
| 6301 | SARS | LZE8T | Human | Esophagus | ESCC | 7.69e-09 | 6.74e-02 | 0.067 |
| 6301 | SARS | LZE22T | Human | Esophagus | ESCC | 8.74e-04 | 3.08e-01 | 0.068 |
| 6301 | SARS | LZE24T | Human | Esophagus | ESCC | 1.32e-07 | 4.18e-01 | 0.0596 |
| 6301 | SARS | LZE6T | Human | Esophagus | ESCC | 1.54e-05 | 1.38e-01 | 0.0845 |
| 6301 | SARS | P1T-E | Human | Esophagus | ESCC | 7.82e-06 | 5.27e-01 | 0.0875 |
| 6301 | SARS | P2T-E | Human | Esophagus | ESCC | 2.64e-41 | 1.11e+00 | 0.1177 |
| 6301 | SARS | P4T-E | Human | Esophagus | ESCC | 8.93e-28 | 6.66e-01 | 0.1323 |
| 6301 | SARS | P5T-E | Human | Esophagus | ESCC | 1.19e-19 | 7.01e-01 | 0.1327 |
| 6301 | SARS | P8T-E | Human | Esophagus | ESCC | 2.33e-21 | 4.50e-01 | 0.0889 |
| 6301 | SARS | P9T-E | Human | Esophagus | ESCC | 7.76e-25 | 3.66e-01 | 0.1131 |
| 6301 | SARS | P10T-E | Human | Esophagus | ESCC | 1.82e-38 | 8.08e-01 | 0.116 |
| 6301 | SARS | P11T-E | Human | Esophagus | ESCC | 7.18e-16 | 7.92e-01 | 0.1426 |
| 6301 | SARS | P12T-E | Human | Esophagus | ESCC | 1.21e-71 | 1.82e+00 | 0.1122 |
| 6301 | SARS | P15T-E | Human | Esophagus | ESCC | 3.78e-28 | 6.11e-01 | 0.1149 |
| 6301 | SARS | P16T-E | Human | Esophagus | ESCC | 2.39e-24 | 7.11e-01 | 0.1153 |
| 6301 | SARS | P17T-E | Human | Esophagus | ESCC | 2.78e-18 | 1.04e+00 | 0.1278 |
| 6301 | SARS | P19T-E | Human | Esophagus | ESCC | 1.41e-06 | 1.13e+00 | 0.1662 |
| 6301 | SARS | P20T-E | Human | Esophagus | ESCC | 1.56e-15 | 4.74e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006418 | Colorectum | AD | tRNA aminoacylation for protein translation | 19/3918 | 41/18723 | 2.37e-04 | 3.03e-03 | 19 |
| GO:0043039 | Colorectum | AD | tRNA aminoacylation | 19/3918 | 44/18723 | 7.13e-04 | 7.21e-03 | 19 |
| GO:0043038 | Colorectum | AD | amino acid activation | 19/3918 | 45/18723 | 9.94e-04 | 9.28e-03 | 19 |
| GO:0006520 | Colorectum | AD | cellular amino acid metabolic process | 81/3918 | 284/18723 | 1.37e-03 | 1.19e-02 | 81 |
| GO:00064181 | Colorectum | SER | tRNA aminoacylation for protein translation | 17/2897 | 41/18723 | 5.75e-05 | 1.35e-03 | 17 |
| GO:00430391 | Colorectum | SER | tRNA aminoacylation | 17/2897 | 44/18723 | 1.64e-04 | 3.12e-03 | 17 |
| GO:00430381 | Colorectum | SER | amino acid activation | 17/2897 | 45/18723 | 2.25e-04 | 3.91e-03 | 17 |
| GO:00065201 | Colorectum | SER | cellular amino acid metabolic process | 61/2897 | 284/18723 | 4.20e-03 | 3.41e-02 | 61 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00009592 | Esophagus | ESCC | mitochondrial RNA metabolic process | 39/8552 | 49/18723 | 1.20e-06 | 1.49e-05 | 39 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:01400531 | Liver | HCC | mitochondrial gene expression | 82/7958 | 108/18723 | 1.49e-12 | 7.20e-11 | 82 |
| GO:00325431 | Liver | HCC | mitochondrial translation | 62/7958 | 76/18723 | 2.95e-12 | 1.34e-10 | 62 |
| GO:00065202 | Liver | HCC | cellular amino acid metabolic process | 167/7958 | 284/18723 | 1.91e-08 | 4.56e-07 | 167 |
| GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
| GO:0000959 | Liver | HCC | mitochondrial RNA metabolic process | 30/7958 | 49/18723 | 6.31e-03 | 2.57e-02 | 30 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SARS | SNV | Missense_Mutation | c.1525N>A | p.Gln509Lys | p.Q509K | protein_coding | tolerated(0.31) | probably_damaging(0.93) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| SARS | SNV | Missense_Mutation | novel | c.530T>G | p.Val177Gly | p.V177G | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| SARS | SNV | Missense_Mutation | c.1132N>T | p.Asp378Tyr | p.D378Y | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SARS | SNV | Missense_Mutation | c.731N>T | p.Asp244Val | p.D244V | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| SARS | SNV | Missense_Mutation | c.1493N>A | p.Ile498Asn | p.I498N | protein_coding | deleterious(0.03) | probably_damaging(0.924) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | ||
| SARS | insertion | Frame_Shift_Ins | novel | c.1072_1073insCATCCTGGCTCCAGCTTTTCCTCTCATTG | p.Tyr359SerfsTer14 | p.Y359Sfs*14 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| SARS | deletion | In_Frame_Del | novel | c.758_778delNNNNNNNNNNNNNNNNNNNNN | p.Lys253_Asp260delinsAsn | p.K253_D260delinsN | protein_coding | TCGA-E9-A3QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |||
| SARS | insertion | Frame_Shift_Ins | novel | c.158_159insG | p.Asn54GlufsTer24 | p.N54Efs*24 | protein_coding | TCGA-Z7-A8R6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |||
| SARS | SNV | Missense_Mutation | rs745648414 | c.1280N>G | p.Ser427Cys | p.S427C | protein_coding | tolerated(0.06) | benign(0.157) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SARS | SNV | Missense_Mutation | novel | c.81N>G | p.Phe27Leu | p.F27L | protein_coding | deleterious(0.01) | possibly_damaging(0.868) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |